Nitto Denko takes over Avecia Biotechnology

Boosts base in emerging nucleic acid drugs market

Nitto Denko Corporation, a Japan-based materials manufacturer, has acquired Avecia Biotechnology, through its New Jersey-based subsidiary Nitto Americas.

Located in Milford, Massachusetts, Avecia Biotechnology is a leader in therapeutic nucleic acid manufacturing and development services. The company provides contract services for DNA and RNA based therapeutics from the pre-clinical stage to commercial launch.

In addition to cGMP (current Good Manufacturing Practices) manufacturing, Avecia Biotechnology's services include the development of analytical methods, process validation, stability studies, quality control, and regulatory support.

Nitto Denko said the purchase would enable it to strengthen its nucleic acid drugs business, which has strong growth potential.

The company is already active in this business through its wholly owned US subsidiary Nitto Denko Technical Corporation, based in Oceanside, California. NDT is currently expanding its technological development of the chemical synthesis of nucleic acid drugs.

Companies